Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation Therapy.

Voog, Justin C; Paulus, Rebecca; Efstathiou, Jason A

Voog, Justin C; Paulus, Rebecca; Efstathiou, Jason A.

Afiliação

Voog JC; Harvard Radiation Oncology Program, Boston, MA, USA.
Paulus R; NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA.
Efstathiou JA; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA,. Electronic address: jefstathiou@partners.org.

Eur Urol ; 69(2): 212-3, 2016 Feb.

Article em En | MEDLINE | ID: mdl-26443430

Assuntos

Antagonistas de Androgênios/uso terapêutico; Neoplasias da Próstata; Humanos; Masculino

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antagonistas de Androgênios Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google